Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
|ClinicalTrials.gov Identifier: NCT01141725|
Recruitment Status : Completed
First Posted : June 10, 2010
Results First Posted : August 18, 2017
Last Update Posted : August 18, 2017
|Condition or disease||Intervention/treatment||Phase|
|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) de Novo Myelodysplastic Syndromes Myelodysplastic Syndrome With Isolated Del(5q) Untreated Adult Acute Myeloid Leukemia||Drug: bendamustine hydrochloride Drug: idarubicin||Phase 1 Phase 2|
I. The maximum tolerated dose (MTD) that is associated with a complete remission (CR) rate of at least 40%, and a rate of grade 3-4 extramedullary toxicity < 30% in patients aged 50 or older with previously untreated AML or high-risk MDS.
I. The disease-free survival (DFS), and overall survival (OS) after therapy at each level of the dosing strategy.
OUTLINE: This is a phase I, dose-escalation study of bendamustine hydrochloride followed by a phase II study.
Patients receive bendamustine hydrochloride intravenously (IV) on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then annually thereafter for 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||39 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome|
|Study Start Date :||September 2010|
|Primary Completion Date :||November 2012|
|Study Completion Date :||November 2012|
Experimental: Treatment (combination chemotherapy)
Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Drug: bendamustine hydrochloride
Other Names:Drug: idarubicin
- Response [ Time Frame: 6 months ]Assessed by cytogenetics/fluorescence in situ hybridization (FISH) and flow cytometry of blood and bone marrow samples. The response criteria defined by Cheson et al. will be used in this study. These criteria are: morphologic leukemia-free state; morphologic complete remission (CR); cytogenetic CR (CRc); molecular CR (CRm); morphologic CR with incomplete blood count recovery (CRi); partial remission (PR); treatment failure; recurrence (progressive disease).
- Incidence of Greater Than or Equal to Grade 3 Toxicity [ Time Frame: Up to day +100 after end of therapy or until the patient received an alternative treatment for leukemia, whatever happens earlier ]Toxicities will be graded using the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0.
- Maximum Tolerated Dose [ Time Frame: 6 months ]A bayesian approach to estimate the MTD of bendamustine associated with a CR rate of at least 40% and with <30% grade 3-4 non-haematological toxicity was used (Wathen et al, 2008).The MTD of bendamustine in combination with idarubicin was determined after two cases of grade 3 toxicity were noted in the three patients entered at the 75 mg/m2 dose. The DLTs were congestive heart failure and mucositis in one patient each. Patients subsequent to this were treated at the 60 mg/m2 bendamustine dose.
- Median Survival [ Time Frame: 5 years ]In a five year following, the median survival was obtained.
- Disease-free Survival (DFS) [ Time Frame: 5 years ]In a five year following, the disease free survival was obtained.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01141725
|United States, Washington|
|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||John Pagel||Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|